In Ang II-infused hypertensive rats, AT1 receptor blockade with olmesartan prevented the augmentation of kidney angiotensinogen (1.14 vs 1.69 densitometric units) and urinary angiotensinogen excretion.
Does AT1 receptor blockade with olmesartan prevent the augmentation of intrarenal angiotensinogen in Ang II-infused hypertensive rats?
Absolute Event Rate: 1.14% vs 1.69%
Angiotensin (Ang) II-infused hypertensive rats exhibit increases in renal angiotensinogen mRNA and protein, as well as urinary angiotensinogen excretion in association with increased intrarenal Ang II content. The present study was performed to determine if the augmentation of intrarenal angiotensinogen requires activation of Ang II type 1 (AT1) receptors. Male Sprague-Dawley rats (200 to 220 g) were divided into 3 groups: sham surgery (n=10), subcutaneous infusion of Ang II (80 ng/min, n=11), and Ang II infusion plus AT1 blocker (ARB), olmesartan (5 mg/d, n=12). Ang II infusion progressively increased systolic blood pressure (SBP) compared with sham (178+/-8 mm Hg versus 119+/-4 at day 11). ARB treatment prevented hypertension (113+/-6 at day 11). Twenty-four-hour urine collections were taken at day 12, and plasma and tissue samples were harvested at day 13. The Ang II+ARB group had a significant increase in plasma Ang II compared with Ang II and sham groups (365+/-46 fmol/mL versus 76+/-9 and 45+/-14, respectively). Nevertheless, ARB treatment markedly limited the enhancement of kidney Ang II by Ang II infusion (65+/-17 fmol/g in sham, 606+/-147 in Ang II group, and 288+/-28 in Ang II+ARB group). Ang II infusion significantly increased kidney angiotensinogen compared with sham (1.69+/-0.21 densitometric units versus 1.00+/-0.17). This change was reflected by increased angiotensinogen immunostaining in proximal tubules. ARB treatment prevented this increase (1.14+/-0.12). Urinary angiotensinogen excretion rates were enhanced 4.7x in Ang II group (4.67+/-0.41 densitometric units versus 1.00+/-0.21) but ARB treatment prevented the augmentation of urinary angiotensinogen (0.96+/-0.23). These data demonstrate that augmentation of intrarenal angiotensinogen in Ang II-infused rats is AT1-dependent and provide further evidence that urinary angiotensinogen is closely linked to intrarenal Ang II in Ang II-dependent hypertension.
Kobori et al. (Tue,) conducted a other in Angiotensin II-Dependent Hypertension (n=33). AT1 blocker (ARB), olmesartan vs. Sham surgery and Ang II infusion alone was evaluated on Kidney angiotensinogen levels (densitometric units). In Ang II-infused hypertensive rats, AT1 receptor blockade with olmesartan prevented the augmentation of kidney angiotensinogen (1.14 vs 1.69 densitometric units) and urinary angiotensinogen excretion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: